Section I important tips, contents and definitions
The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee that the contents of the annual report are true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities.
Xie Xiaolin, the person in charge of the company, Zhu Fengming, the person in charge of accounting, and Cheng Qian, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in this annual report.
All directors have attended the meeting of the board of directors to consider this report.
This report involves forward-looking statements such as future plans and performance forecasts, which do not constitute the company’s substantive commitment to the majority of investors. Investors and relevant persons should maintain sufficient risk awareness and understand the differences between plans, forecasts and commitments. Please pay attention to investment risks and invest rationally.
For details, see “Xi. Prospect of the company’s future development: (III) risk factors and Countermeasures Affecting the company’s future development” in “section III Management Discussion and analysis” of this report.
The profit distribution plan approved by the board of directors is: take 8554360000 shares as the base, distribute cash dividend of 1.80 yuan (including tax) to all shareholders for every 10 shares, send bonus shares of 0 shares (including tax), and do not use accumulation fund to increase share capital.
Speech by the chairman of 2021 Annual Report
Xie Xiaolin
In the year of xinchou, the great epidemic examination, the century change accelerated the evolution, the international situation was treacherous, and the socio-economic development became more complex and severe. The historical objectives of China’s “two centenaries” met, and the new journey of building a modern socialist country was fully opened. At the same time, we got the first report card on the new way to catch up with the examination: the marketing performance goes against the trend, the strategic track is clearer, the project layout is laid out, the scientific research leads to a breakthrough, and the social public welfare is solid and effective In the tide of the new era, Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) is trying to rely on its own strength to walk out of a path of self-reliance, hard work, innovation and development. Compared with the figures in the annual report, I would like to share with you this firm development toughness. Where does the “confidence” come from? In those days when we were “Besieged” by the epidemic, what breakthroughs can we seek? What are our long-term preparations for the future? Reviewing the development history of Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) is a true portrayal and echo of the times that inheritance is not ancient and innovation is inseparable from religion. Mr. Wang chenglao, a legendary grass doctor in Qinling Mountains, used his superb medical skills to heal the wounded of the Red Army and relieve the pain of tens of thousands of patients with bone injuries. He was cordially received by Premier Zhou Enlai twice to create and offer a unique secret recipe of traditional Chinese medicine for the treatment of rheumatic bone injuries, “Panlong Qi”. With the profound Chinese civilization of more than 5000 years as the foundation, he condensed and spread the noble medical ethics and superb medical skills, It has made unique contributions to the health cause of the motherland. Twenty five years ago, Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) it was under the influence of the noble qualities of Wang Jiacheng’s medical ethics, benevolence, excellence, saving lives and danger, honesty and trustworthiness that Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) started from scratch, made reform and innovation, made steady progress, and shouldered the glorious mission of promoting the development of the great cause of traditional Chinese medicine and helping to overcome poverty. All these things complement each other with integrity and innovation. What is hidden in the duet of “defense” and “creation” is the unchanged original heart, which is our “foundation”. In the inheritance of traditional Chinese medicine, there is a phenomenon that the theoretical basis of traditional Chinese medicine is weak, the cultivation of medicinal materials is Jerry built, and acts wantonly. It only wants to be passable, not strong, and bad money expels good money. As everyone knows, forgetting to lose your roots and deviate from the right path is tantamount to self destruction and abandonment. “Upholding integrity” means that we should be able to uphold the original intention, the foundation, the essence and the position. Therefore, we focus on our main business, practice our internal skills, adhere to seeking progress while maintaining stability, strive to strengthen modern traditional Chinese medicine with the purpose of strengthening the main body of the pharmaceutical industry, and firmly grasp the development core of traditional Chinese medicine, such as traditional Chinese medicine decoction pieces, hospital preparations, formula particles, classic famous prescriptions and great health industry. The planting base of traditional Chinese medicine established in the early years ensures the traceable product quality from the source. The annual output value of the upcoming smart chemical plant is expected to increase by five times, the technical level and scale efficiency will increase significantly, and the traditional Chinese medicine pharmacy will further move towards standardization and greening. On the road of accelerating the modernization of traditional Chinese medicine and building the whole chain of industrialization of traditional Chinese medicine, we should establish a firm concept, assume responsibility and run out of the acceleration. These are the key to “keeping integrity” and the foundation for inheriting and carrying forward traditional Chinese medicine. Since ancient times, traditional Chinese medicine has adhered to the endowment of “self-improvement, virtue and material”, “the way of all benefits, go with the times” and “new reasons push each other, and life does not lag” of the excellent traditional Chinese culture, forming the style of seeking change and new products of the noumenon. Standing at the forefront of the new era, Panlong people have absorbed historical nutrition, kept pace with the times, gradually explored and drawn a strategic blueprint for the development of “one body and two wings”, strengthened scientific and technological innovation and emphasized an international vision. After policy changes, market baptism and epidemic impact, our strategy has shown strong vitality in spite of rain and wind. We take promoting the development of “Qinyao” as our own responsibility, focus on the overall situation of entity operation and capital operation, focus on “specialty, precision, specialty and innovation”, adhere to the scientific research idea of “grasping the cutting edge and combining innovation with imitation”, make full use of the new model of “collaborative innovation platform of government, industry, University and research”, jointly build the “government, industry, University and research” platform with many first-class scientific research institutes and medical institutions, and rely on Panlong from preliminary research, production and listing to approval and listing The transformation ability of the whole chain R & D achievements promoted by the terminal, as well as the infrastructure, talent reserve and financial strength connecting each link, focus on the development breakthrough of new traditional Chinese medicine, hospital preparations, formula particles and classic famous prescriptions. At present, the two key projects of hospital preparations and traditional Chinese medicine formula particles are also being fully promoted. Covid-19 pneumonia is rampant. We have entered the field of biochemical drugs on a large scale, actively sought to explore the anti epidemic weapon, jointly developed the “coronavirus 3CL protease inhibitor” project with Shaanxi University of science and technology, and preliminarily constructed the anti covid-19 virus drug patent pool in a milestone way. At present, in the preclinical research stage, we hope that the project can become a medical weapon to save lives and control the epidemic situation, Inject powerful traditional Chinese medicine into the construction of human health community. In the field of biomedicine and the big health industry, we have never stopped. We have also continued to expand commercial logistics and retail terminals and build a new development pattern. The big health products currently on the market, such as Panlong 7 toothpaste and facial mask, have won hot pursuit and unanimous praise from consumers after entering the market. In the capital market, we belong to the “new generation”. Adhering to long-term ism is our style. The stock market should be a weighing machine rather than a hair dryer. We have been working hard to make Panlong a more “heavy” company. The new industrial fund has been established and will make rapid efforts in the field of orthopedics and traumatology, sports medicine and new biological drugs. Convertible bonds have been publicly issued at the beginning of this month and will make major breakthroughs in traditional Chinese medicine innovation, new drug development, product quality improvement and promoting the large-scale development of the industry Nothingness and ethereal will never be in Panlong’s dictionary. We have spent many years deeply laying down foreshadows, ready to seize opportunities at any time, follow the trend and outline a new territory.
We are also well aware that the innovation and transformation of system and mechanism is a protracted war that can not wait but can not be rushed. It is the quickest path in the long journey to focus on running our own affairs—— We will spare no effort to accelerate the implementation of digital transformation and further explore the value of data in industry marketing and tools combined with business scenarios—— We should continue to promote the reform of system and mechanism, increase policy support with unprecedented strength, promote the incentive mechanism with unprecedented confidence and determination, constantly break the habitual thinking and improve the vitality of the organization—— We should deeply develop the first resource of talents, vigorously optimize the talent structure, and establish a perfect, efficient and flexible talent training and competition mechanism to make talents have a place to play. Practice has proved that traditional Chinese medicine has lasted for a long time and depends on the integration of inheritance and innovation. Inheritance brings innovation and innovation drives development. Integrity and innovation are born together. Only by adhering to integrity can innovation have the right direction. Continuous innovation can strengthen the foundation. Without inheritance, innovation will lose its foundation. Without innovation, inheritance will lose its future. Last year, I mentioned in my speech in the annual report: the times are endless, and Panlong keeps walking. In this turbulent new era, we continue to steadily and stride forward the inheritance, innovation and development of traditional Chinese medicine, enrich the essence of traditional Chinese medicine enterprises, highlight the charm of traditional Chinese medicine, sing about cultural self-confidence and cultural self-improvement, make greater contributions to the health and well-being of all mankind, show the sacred historical mission and responsibility of contemporary traditional Chinese medicine people, and continue to create value for investors. We firmly believe: to the future together. We hope: common destiny and world peace.
catalogue
Section I important tips, contents and definitions Section 2 company profile and main financial indicators 10 section III Management Discussion and Analysis Section IV corporate governance Section V environmental and social responsibility Section VI important matters Section VII changes in shares and shareholders 81 Section VIII preferred shares 87 section IX relevant information of bonds 88 section x financial report eighty-nine
Directory of documents for future reference
1. Financial statements containing the signatures and seals of the legal representative of the company, the person in charge of accounting and the person in charge of accounting institutions; 2. The original of the audit report sealed by the accounting firm and signed and sealed by the certified public accountant; 3. The originals of all company documents and announcements publicly disclosed by China Securities Journal, Shanghai Securities News, Securities Daily, securities times and cninfo during the reporting period.
interpretation
Explanatory item refers to the explanatory content
Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) , the company, the joint stock company and the company refer to Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864)
Shaanxi Pharmaceutical Co., Ltd
Panlong plant pharmaceutical refers to Shaanxi Shangluo Panlong Plant Pharmaceutical Co., Ltd
Panlong Pharmaceutical Research Institute refers to Shaanxi Panlong Pharmaceutical Research Institute
Gansu Panlong refers to Gansu Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) Co., Ltd
Panlong health products refers to Shaanxi Pharmaceutical Co., Ltd
Bohua pharmaceutical refers to Shaanxi Bohua Pharmaceutical Co., Ltd
Qinmai medical refers to Shaanxi Qinmai medical preparation centralized configuration Co., Ltd
CSRC refers to the China Securities Regulatory Commission
Shenzhen Stock Exchange and stock exchange refer to Shenzhen Stock Exchange
Zhongtai Securities Co.Ltd(600918) , sponsor and lead underwriter refer to Zhongtai Securities Co.Ltd(600918)
Audit institution and Lixin certified public accountants refer to Lixin Certified Public Accountants (special general partnership)
The reporting period refers to the period from January 1, 2021 to December 31, 2021
Company Law refers to the company law of the people’s Republic of China
Securities Law refers to the securities law of the people’s Republic of China
Yuan and 10000 yuan refer to RMB yuan / 10000 yuan unless otherwise specified
The catalogue of drugs for national basic medical insurance, industrial injury insurance and maternity insurance (hereinafter referred to as the catalogue of drugs for national medical insurance) is the standard for the payment of drug expenses by the funds for basic medical insurance, industrial injury insurance and maternity insurance. The prescription issued by the clinician according to the condition and the purchase and use of drugs by the insured are not restricted by the drug catalogue.
GMP refers to the good manufacturing practice
Prescription drugs refer to drugs that can only be dispensed, purchased and used with the prescription of a licensed doctor or a licensed assistant doctor
Over the counter drugs and OTC drugs refer to drugs selected by experts that can be purchased and used by patients after long-term clinical practice and can ensure safety
Also known as authentic medicinal materials, it is a special term for high-quality and pure medicinal materials. It refers to medicinal materials with long history, suitable place of origin, excellent varieties, high yield, exquisite processing, outstanding curative effect and regional characteristics
